Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo

Main Article Content

Jenny E. Murase
Monica Munera-Campos
H. Chih-ho Hong
Alain Taieb
Wen-Hung Chung
Amber Reck Atwater
Maria Jose Rueda
Jinglin Zhong
Maria Lucia Buziqui Piruzeli
Ignasi Pau-Charles
Mette Deleuran


Lebrikizumab, atopic dermatitis, erythema


1. Kozera E, et al. Br J Dermatol. 2022;186:1050-1052.

2. Uchida H, et al. J Eur Acad Dermatol Venereol. 2023;37:e300-e302.

3. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

4. Guttman-Yassky E, et al. JAMA Dermatol. 2020;156:411-420.

5. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

6. Simpson EL, et al. JAMA Dermatol. 2023;159:182-191.

7. Paller AS, et al. Dermatol Ther (Heidelb). 2023;13:1517-1534.

8. Stein Gold L, et al. Am J Clin Dermatol. 2023;24:595-607.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>